Indoor Air Pollution, CT Airway-to-Lung Ratio and Lung Function Decline: Analyses from SPIROMICS AIR

SPIROMICS AIR was supported by National Institute of Environmental Health Sciences grant R01ES023500. SPIROMICS was supported by NHLBI contracts HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN268200900019C, and HHSN268200900020C; NHLBI grants U01 HL137880, U24 HL141762, R01 HL182622, and R01 HL144718; and supplemental contributions made through the Foundation for the NIH and the COPD Foundation from Amgen, AstraZeneca/MedImmune, Bayer, Bellerophon Therapeutics, Boehringer Ingelheim Pharmaceuticals, Inc., Chiesi Farmaceutici S.p.A., Forest Research Institute, Inc., Genentech, GlaxoSmithKline, Grifols Therapeutics, Inc., Ikaria, Inc., MGC Diagnostics, Novartis Pharmaceuticals Corporation, Nycomed GmbH, Polarean, ProterixBio, Regeneron Pharmaceuticals, Inc., Sanofi, Sunovion, Takeda Pharmaceutical Company, and Theravance Biopharma and Mylan/Viatris. This work was also supported by National Institute of Minority Health and Health Disparities grant DP50MD010431/Environmental Protection Agency grant 83615001 (N.N.H.) and NHLBI grant K23HL164151 (S.R.) . The views expressed in this document are solely those of the authors and do not necessarily reflect those of the agencies. The Environmental Protection Agency does not endorse any products or commercial services mentioned in this publication.